Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature
暂无分享,去创建一个
A. Gadducci | S. Cosio | Angiolo Gadducci | Stefania Cosio | L. Domenici | Cecilia Barsotti | Lavinia Domenici | Andrea Riccardo Genazzani | C. Barsotti | A. Riccardo Genazzani
[1] S. de Sanjosé,et al. The Epidemiology of Human Papillomavirus Infection and Cervical Cancer , 2007, Disease markers.
[2] A. Ferenczy,et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. , 1997, British Journal of Cancer.
[3] Ming Yan,et al. Modulation of IL-6 Production during the Menstrual Cycle in Vivo and in Vitro , 2000, Brain, Behavior, and Immunity.
[4] M. Schiffman,et al. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. , 1992, Journal of the National Cancer Institute.
[5] S. Klein,et al. The effects of hormones on sex differences in infection: from genes to behavior , 2000, Neuroscience & Biobehavioral Reviews.
[6] B. Stillman,et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. , 1997, Genes & development.
[7] M. Vessey,et al. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004 , 2006, British Journal of Cancer.
[8] M. Kazatchkine,et al. Increased Risk of Cervical Disease Among Human Immunodeficiency Virus–Infected Women With Severe Immunosuppression and High Human Papillomavirus Load , 2000, Obstetrics and gynecology.
[9] A. P. Frank. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. , 2008, The New England journal of medicine.
[10] D Hoffmann,et al. Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. , 1999, Cancer letters.
[11] J. Irache,et al. Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams. , 2006, Vaccine.
[12] H. Stephens. HIV-1 diversity versus HLA class I polymorphism. , 2005, Trends in immunology.
[13] I. Takač,et al. Use of various contraceptives and human papillomavirus 16 and 18 infections in women with cervical intraepithelial neoplasia , 2010, International journal of STD & AIDS.
[14] C. Herrington,et al. Differential cell cycle regulation by low- and high-risk human papillomaviruses in low-grade squamous intraepithelial lesions of the cervix. , 1998, Cancer research.
[15] R. Hoover,et al. Risk of cancer in women receiving hormone replacement therapy , 1989, International journal of cancer.
[16] M. Stämpfli,et al. How cigarette smoke skews immune responses to promote infection, lung disease and cancer , 2009, Nature Reviews Immunology.
[17] N. Dyson,et al. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression , 2004, Journal of Cell Science.
[18] K. Tamaki,et al. Estrogen enhances immunoglobulin production by human PBMCs. , 1999, The Journal of allergy and clinical immunology.
[19] S. Jick,et al. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations , 2009, Climacteric : the journal of the International Menopause Society.
[20] M. Plummer,et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study , 2003, Cancer Causes & Control.
[21] Young Tae Kim,et al. Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors. , 2002, Yonsei medical journal.
[22] J. Dillner,et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. , 2006, Vaccine.
[23] M. Schiffman,et al. Human Papillomavirus Epidemiology and Public Health , 2022 .
[24] T. Sasagawa,et al. Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection , 2008, Journal of medical virology.
[25] J. Schlesselman,et al. Safety concerns and health benefits associated with oral contraception. , 2004, American journal of obstetrics and gynecology.
[26] U. Musharrafieh,et al. Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[27] M P Vessey,et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20–44 years: the UK National Case–Control Study of Cervical Cancer , 2003, British Journal of Cancer.
[28] J. Moodley. Combined oral contraceptives and cervical cancer , 2004, Current opinion in obstetrics & gynecology.
[29] K. Matsuo,et al. HLA-A Alleles and the Risk of Cervical Squamous Cell Carcinoma in Japanese Women , 2010, Journal of epidemiology.
[30] G. Marshall,et al. Perimenstrual alterations in type-1/type-2 cytokine balance of normal women. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[31] A. van Assche,et al. Tobacco smoking impairs the local immunosurveillance in the uterine cervix. An immunohistochemical study. , 1995, Gynecologic and obstetric investigation.
[32] M. Chiasson,et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. , 2000, JAMA.
[33] R. Weinberg,et al. Control of the cell cycle and apoptosis. , 1999, European journal of cancer.
[34] Y. Rosenstein,et al. Oestradiol potentiates the suppressive function of human CD4+ CD25+ regulatory T cells by promoting their proliferation , 2006, Immunology.
[35] J. Cuzick,et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.
[36] M. B. Diouf,et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. , 2003, Journal of Infectious Diseases.
[37] S. Ziegler,et al. Functional Analysis of FOXP3 , 2008, Annals of the New York Academy of Sciences.
[38] A. Seidel,et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. , 1998, Carcinogenesis.
[39] D. Chan,et al. Risk association between human leukocyte antigen-A allele and high-risk human papillomavirus infection for cervical neoplasia in Chinese women. , 2005, The Journal of infectious diseases.
[40] S. Shapiro,et al. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) , 2003, Cancer Causes & Control.
[41] Xavier Castellsagué,et al. Chapter 1: HPV in the etiology of human cancer. , 2006, Vaccine.
[42] N. Muñoz,et al. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. , 2003, Journal of the National Cancer Institute. Monographs.
[43] Stephen D Walter,et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. , 2007, The New England journal of medicine.
[44] B. Clarke,et al. Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. , 2001, Gynecologic oncology.
[45] C. la Vecchia,et al. Hormonal contraception and risk of cancer. , 2010, Human reproduction update.
[46] A. Hoitsma,et al. Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients , 2010, Transplant international : official journal of the European Society for Organ Transplantation.
[47] C. Fiorentini,et al. The Rho-activating CNF1 toxin from pathogenic E. coli: A risk factor for human cancer development? , 2008, Infectious Agents and Cancer.
[48] E. Androphy,et al. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. , 2000, Cancer research.
[49] L. Ahdieh,et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. , 2001, The Journal of infectious diseases.
[50] E. Kliewer,et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. , 2009, Gastroenterology.
[51] S. Syrjänen,et al. Papillomavirus Infections in Human Pathology , 2000 .
[52] A. Gadducci,et al. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. , 2009, Critical reviews in oncology/hematology.
[53] M. Oehler,et al. Hormone replacement after gynaecological cancer. , 2010, Maturitas.
[54] A. Schulze,et al. Anchorage-Independent Transcription of the Cyclin A Gene Induced by the E7 Oncoprotein of Human Papillomavirus Type 16 , 1998, Journal of Virology.
[55] E. de Villiers. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma , 2003, International journal of cancer.
[56] C. Lees,et al. Lack of association between cervical dysplasia and IBD: A large case–control study , 2009, Inflammatory bowel diseases.
[57] M. Vessey,et al. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. , 2010, Contraception.
[58] R. Eastell,et al. The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. , 2001, Bone.
[59] Wei-Yuan Zhang,et al. A Population-based Study on the Risks of Cervical Lesion and Human Papillomavirus Infection among Women in Beijing, People's Republic of China , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[60] V. Beral,et al. Cervical cancer and use of hormonal contraceptives: a systematic review , 2003, The Lancet.
[61] S. Waggoner,et al. Identification of Tobacco- Specific Carcinogen in the Cervical Mucus of Smokers and Nonsmokers , 1997 .
[62] E. Ploch. Hormonal replacement therapy in patients after cervical cancer treatment. , 1987, Gynecologic oncology.
[63] M. Polan,et al. Ovarian steroids modulate human monocyte tumor necrosis factor alpha messenger ribonucleic acid levels in cultured human peripheral monocytes. , 1992, Fertility and sterility.
[64] J. Dillner,et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection , 2000, British Journal of Cancer.
[65] A. Moune,et al. Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy , 2009, Infectious Agents and Cancer.
[66] L. Hengst,et al. Inhibitors of the Cip/Kip family. , 1998, Current topics in microbiology and immunology.
[67] V. Moreno,et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study , 2002, The Lancet.
[68] Y. Hirai,et al. Tobacco smoking and regression of low‐grade cervical abnormalities , 2010, Cancer science.
[69] V. Beral,et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies , 2007, The Lancet.
[70] M. Diamond,et al. Progesterone and estradiol modulate interleukin-1 beta messenger ribonucleic acid levels in cultured human peripheral monocytes. , 1989, The Journal of clinical endocrinology and metabolism.
[71] S. Gange,et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. , 2004, Journal of the National Cancer Institute.
[72] Helen Trottier,et al. The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.
[73] D. Hellberg,et al. The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer. , 2005, Anticancer research.
[74] R. Chetty,et al. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: A review , 2002, International Journal of Gynecologic Cancer.
[75] P. Adams. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. , 2001, Biochimica et biophysica acta.
[76] A. Berrington de González,et al. Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis , 2004, British Journal of Cancer.
[77] E. Korobowicz,et al. Prevalence of Chlamydia trachomatis and herpes simplex virus 2 in cervical carcinoma associated with human papillomavirus detected in paraffin-sectioned samples. , 2009, European journal of gynaecological oncology.
[78] S. Kjaer,et al. Case—control study of risk factors for cervical squamous cell neoplasia in Denmark, IV: role of smoking habits , 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[79] S. Alam,et al. The Cigarette Smoke Carcinogen Benzo[a]pyrene Enhances Human Papillomavirus Synthesis , 2007, Journal of Virology.
[80] W. Quint,et al. Effect of the Menstrual Cycle and Hormonal Contraceptives on Human Papillomavirus Detection in Young, Unscreened Women , 2010, Obstetrics and gynecology.
[81] H. Yoshida,et al. [Machinery of programmed cell death]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.
[82] E. Androphy,et al. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. , 2000, Cancer research.
[83] E. Villiers. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. , 2003 .
[84] K. Beagley,et al. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. , 2003, FEMS immunology and medical microbiology.
[85] S. Syrjänen,et al. Cell Cycle Regulators p105, p107, Rb2/p130, E2F4, p21CIP1/WAF1, Cyclin A in Predicting Cervical Intraepithelial Neoplasia, High-Risk Human Papillomavirus Infections and Their Outcome in Women Screened in Three New Independent States of the Former Soviet Union , 2006, Cancer Epidemiology Biomarkers & Prevention.
[86] L. Zhao,et al. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. , 2008, Cancer research.
[87] E. Armstrong,et al. Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types , 2010, Journal of managed care pharmacy : JMCP.
[88] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.
[89] J. Peto,et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case–control study nested within the Manchester cohort , 2000, British Journal of Cancer.
[90] P. Sismondi,et al. Hormone replacement therapy in cancer survivors. , 2004, Maturitas.
[91] D. Celentano,et al. The association of hormonal contraceptive use and HPV prevalence , 2011, International journal of cancer.
[92] A. Lazzarin,et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. , 2001, The Journal of infectious diseases.
[93] J. Jönsson,et al. Systemic Reduction of Functionally Suppressive CD4dimCD25highFoxp3+ Tregs in Human Second Trimester Pregnancy Is Induced by Progesterone and 17β-Estradiol1 , 2009, The Journal of Immunology.
[94] Charles J. Sherr,et al. The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.
[95] W. Haenszel,et al. Cigarette smoking and invasive cervical cancer. , 1986, JAMA.
[96] K. Anastos,et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. , 2003, Journal of the National Cancer Institute.
[97] S. Mitrani‐Rosenbaum,et al. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. , 1989, The Journal of general virology.
[98] E. Klumb,et al. Is Higher Prevalence of Cervical Intraepithelial Neoplasia in Women With Lupus Due to Immunosuppression? , 2010, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[99] S. Bernatsky,et al. Malignancy in systemic lupus erythematosus: what have we learned? , 2009, Best practice & research. Clinical rheumatology.
[100] C Dosne Pasqualini,et al. The HLA system. , 1979, Medicina.
[101] J. M. van der Hulst,et al. Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 , 2004, Cancer Research.
[102] F. X. Bosch,et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.
[103] S. Rosso,et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. , 2008, The Lancet. Oncology.
[104] C. Schairer,et al. Cancer incidence and mortality in women receiving estrogen and estrogen‐progestin replacement therapy—long‐term follow‐up of a Swedish cohort , 1996, International journal of cancer.
[105] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[106] David R. Scott,et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. , 1994, The Journal of infectious diseases.
[107] Jong Eun Lee,et al. GSTP1 polymorphism, cigarette smoking and cervical cancer risk in Korean women. , 2002, Yonsei medical journal.
[108] H. Burger. Climacteric: The Journal of the International Menopause Society , 1998 .
[109] M. Einstein,et al. Issues in cervical cancer incidence and treatment in HIV , 2010, Current opinion in oncology.
[110] T. Rohan,et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. , 1999, The Journal of infectious diseases.
[111] A. Fiander,et al. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. , 2007, Vaccine.
[112] E. Negri,et al. Case-control study of oestrogen replacement therapy and risk of cervical cancer , 1997, BMJ.
[113] M. Schiffman,et al. Chapter 5: Updating the natural history of HPV and anogenital cancer. , 2006, Vaccine.
[114] J. Cuzick,et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.
[115] S. Klein,et al. Progesterone and 17β-Estradiol Enhance Regulatory Responses to Human Papillomavirus Type 16 Virus-Like Particles in Peripheral Blood Mononuclear Cells from Healthy Women , 2010, Clinical and Vaccine Immunology.
[116] S. Jick,et al. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009 Sep 1:1-11. , 2010 .
[117] J. Dillner,et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. , 2009, Journal of the National Cancer Institute.
[118] G. Creatsas,et al. Oral Contraceptives and Reproductive System Cancer , 2003, Annals of the New York Academy of Sciences.
[119] L. Hinds,et al. Menopause, hormone replacement and gynaecological cancers , 2010, Menopause international.
[120] J. Klein,et al. The HLA system. First of two parts. , 2000, The New England journal of medicine.
[121] M. von Knebel Doeberitz. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. , 2002, European journal of cancer.
[122] N. Kiviat,et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. , 2003, American journal of epidemiology.
[123] B. Patterson,et al. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. , 2011, Gynecologic oncology.